Reasonability of Frequent Laboratory Analyses during Therapy with Nivolumab and Nivolumab+Ipilimumab in Patients with Advanced or Metastatic Renal Cell Carcinoma during the Phase 2 Clinical Trial TITAN-RCC.

Autor: Franke K; Department of Urology, Jena University Hospital, Friedrich-Schiller University, 07747 Jena, Germany.; Comprehensive Cancer Center Central Germany (CCCG), 07743 Jena, Germany., Foller S; Department of Urology, Jena University Hospital, Friedrich-Schiller University, 07747 Jena, Germany.; Comprehensive Cancer Center Central Germany (CCCG), 07743 Jena, Germany., Rosero Moreno ME; Department of Urology, Jena University Hospital, Friedrich-Schiller University, 07747 Jena, Germany.; Comprehensive Cancer Center Central Germany (CCCG), 07743 Jena, Germany., Ali N; Department of Urology, Jena University Hospital, Friedrich-Schiller University, 07747 Jena, Germany.; Comprehensive Cancer Center Central Germany (CCCG), 07743 Jena, Germany., Leistritz L; Comprehensive Cancer Center Central Germany (CCCG), 07743 Jena, Germany.; Institute of Medical Statistics, Informatics and Data Science, Jena University Hospital, Friedrich-Schiller University, 07747 Jena, Germany., Leucht K; Department of Urology, Jena University Hospital, Friedrich-Schiller University, 07747 Jena, Germany.; Comprehensive Cancer Center Central Germany (CCCG), 07743 Jena, Germany., Grimm MO; Department of Urology, Jena University Hospital, Friedrich-Schiller University, 07747 Jena, Germany.; Comprehensive Cancer Center Central Germany (CCCG), 07743 Jena, Germany.

Publikováno v: Cancers [Cancers (Basel)] 2024 Jun 20; Vol. 16 (12). Date of Electronic Publication: 2024 Jun 20.